141 related articles for article (PubMed ID: 36183501)
1. Development and validation of a joint model for dynamic prediction of overall survival in nasopharyngeal carcinoma based on longitudinal post-treatment plasma cell-free Epstein-Barr virus DNA load.
Zhu GL; Fang XL; Yang KB; Tang LL; Ma J
Oral Oncol; 2022 Nov; 134():106140. PubMed ID: 36183501
[TBL] [Abstract][Full Text] [Related]
2. Circulating Epstein-Barr virus DNA level post induction chemotherapy contributes to prognostication in advanced-stage nasopharyngeal carcinoma.
Chen FP; Luo YS; Chen K; Li JY; Huo LQ; Shi L; Ou-Yang Y; Cao XP
Eur J Cancer; 2021 Jul; 151():63-71. PubMed ID: 33964573
[TBL] [Abstract][Full Text] [Related]
3. The value of integrating tumor volume and plasma Epstein-Barr virus DNA load during sequential chemoradiotherapy for prognostic prediction and therapeutic guidance in high-risk locoregionally advanced nasopharyngeal carcinoma.
Wang G; Dong Z; Huang C; Du X; Chen L; Li K; Guo R; Tang L; Ma J
Oral Oncol; 2023 Oct; 145():106500. PubMed ID: 37467683
[TBL] [Abstract][Full Text] [Related]
4. Prognostic potential of liquid biopsy tracking in the posttreatment surveillance of patients with nonmetastatic nasopharyngeal carcinoma.
Chen FP; Huang XD; Lv JW; Wen DW; Zhou GQ; Lin L; Kou J; Wu CF; Chen Y; Zheng ZQ; Li ZX; He XJ; Sun Y
Cancer; 2020 May; 126(10):2163-2173. PubMed ID: 32125701
[TBL] [Abstract][Full Text] [Related]
5. Liquid biopsy posttreatment surveillance in endemic nasopharyngeal carcinoma: a cost-effective strategy to integrate circulating cell-free Epstein-Barr virus DNA.
Wu CF; Lin L; Mao YP; Deng B; Lv JW; Zheng WH; Wen DW; Kou J; Chen FP; Yang XL; Xu SS; Ma J; Zhou GQ; Sun Y
BMC Med; 2021 Aug; 19(1):193. PubMed ID: 34433440
[TBL] [Abstract][Full Text] [Related]
6. Integrating postradiotherapy plasma Epstein-Barr virus DNA and TNM stage for risk stratification of nasopharyngeal carcinoma to adjuvant therapy.
Hui EP; Li WF; Ma BB; Lam WKJ; Chan KCA; Mo F; Ai QYH; King AD; Wong CH; Guo R; Poon DMC; Tong M; Li L; Lau TKH; Wong KCW; Lam DCM; Lo YMD; Ma J; Chan ATC
Ann Oncol; 2020 Jun; 31(6):769-779. PubMed ID: 32217076
[TBL] [Abstract][Full Text] [Related]
7. Long-term monitoring of dynamic changes in plasma EBV DNA for improved prognosis prediction of nasopharyngeal carcinoma.
Li W; Chen J; Liang B; Li Z; Li J; Yuan X; Wu S; Zeng F; Peng X; Li Y; Lu J; Zhao F; Liu X
Cancer Med; 2021 Feb; 10(3):883-894. PubMed ID: 33378109
[TBL] [Abstract][Full Text] [Related]
8. Spontaneous remission of residual post-therapy plasma Epstein-Barr virus DNA and its prognostic implication in nasopharyngeal carcinoma: A large-scale, big-data intelligence platform-based analysis.
Zhang Y; Tang LL; Li YQ; Liu X; Liu Q; Ma J
Int J Cancer; 2019 May; 144(9):2313-2319. PubMed ID: 30485420
[TBL] [Abstract][Full Text] [Related]
9. Proposed modifications and incorporation of plasma Epstein-Barr virus DNA improve the TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma.
Guo R; Tang LL; Mao YP; Du XJ; Chen L; Zhang ZC; Liu LZ; Tian L; Luo XT; Xie YB; Ren J; Sun Y; Ma J
Cancer; 2019 Jan; 125(1):79-89. PubMed ID: 30351466
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of a novel model incorporating serological indicators into the conventional TNM staging system for nasopharyngeal carcinoma.
Ding C; Dai DY; Luo ZK; Wang GY; Dong Z; Qin GJ; Du XJ; Ma J
Oral Oncol; 2024 Apr; 151():106725. PubMed ID: 38430711
[TBL] [Abstract][Full Text] [Related]
11. Prognostic values of the integrated model incorporating the volume of metastatic regional cervical lymph node and pretreatment serum Epstein-Barr virus DNA copy number in predicting distant metastasis in patients with N1 nasopharyngeal carcinoma.
Yao JJ; Zhou GQ; Wang YQ; Wang SY; Zhang WJ; Jin YN; Zhang F; Li L; Liu LZ; Cheng ZB; Ma J; Qi ZY; Sun Y
Chin J Cancer; 2017 Dec; 36(1):98. PubMed ID: 29284539
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of systemic inflammation response index in nasopharyngeal carcinoma with negative Epstein-Barr virus DNA.
Yuan X; Yang H; Zeng F; Zhou S; Wu S; Yuan Y; Cui L; Feng H; Lin D; Chen Z; Liu X; Chen J; Wang F
BMC Cancer; 2022 Aug; 22(1):858. PubMed ID: 35932022
[TBL] [Abstract][Full Text] [Related]
13. Epstein-Barr Virus DNA in Nasopharyngeal Carcinoma: A Brief Review.
Xue F; He X
Methods Mol Biol; 2020; 2204():99-107. PubMed ID: 32710318
[TBL] [Abstract][Full Text] [Related]
14. Plasma Epstein-Barr viral DNA load after completion of two cycles of induction chemotherapy predicts outcomes for patients with advanced-stage nasopharyngeal carcinoma.
Zong J; Ji P; Lin C; Zhang R; Chen Y; Lu Q; Peng X; Pan J; Lin S
Oral Oncol; 2022 Aug; 131():105972. PubMed ID: 35728415
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal post-radiotherapy plasma Epstein-Barr virus DNA trends inform on optimal risk stratification in endemic nasopharyngeal carcinoma.
Neo J; Yip PL; Ong EHW; Miao J; Chow WM; Wee JTS; Fong KW; Soong YL; Tan TWK; Tan JSH; Sin SY; Liu J; Loh KS; Tay JK; Ang MK; Tan SH; Lim DWT; Chua MLK
Oral Oncol; 2024 Jan; 148():106655. PubMed ID: 38056062
[TBL] [Abstract][Full Text] [Related]
16. Plasma Epstein-Barr viral DNA load at midpoint of radiotherapy course predicts outcome in advanced-stage nasopharyngeal carcinoma.
Leung SF; Chan KC; Ma BB; Hui EP; Mo F; Chow KC; Leung L; Chu KW; Zee B; Lo YM; Chan AT
Ann Oncol; 2014 Jun; 25(6):1204-8. PubMed ID: 24638904
[TBL] [Abstract][Full Text] [Related]
17. Nasopharyngeal necrosis contributes to overall survival in nasopharyngeal carcinoma without distant metastasis: a comprehensive nomogram model.
Sun XS; Xiao ZW; Liu SL; Sun R; Luo DH; Chen QY; Mai HQ
Eur Radiol; 2023 May; 33(5):3682-3692. PubMed ID: 36735041
[TBL] [Abstract][Full Text] [Related]
18. Individualized concurrent chemotherapy by pretreatment plasma Epstein-Barr viral DNA in II-III stage nasopharyngeal carcinoma: A propensity score matching analysis using a large cohort.
Sun XS; Chen WH; Liu SL; Liang YJ; Chen QY; Guo SS; Wen YF; Liu LT; Xie HJ; Tang QN; Li XY; Yan JJ; Mai HQ; Tang LQ
Cancer Med; 2019 Aug; 8(9):4214-4225. PubMed ID: 31210417
[TBL] [Abstract][Full Text] [Related]
19. Risk stratification based on change in plasma Epstein-Barr virus DNA load after treatment in nasopharyngeal carcinoma.
Zhang Y; Li WF; Mao YP; Guo R; Tang LL; Peng H; Sun Y; Liu Q; Chen L; Ma J
Oncotarget; 2016 Feb; 7(8):9576-85. PubMed ID: 26840023
[TBL] [Abstract][Full Text] [Related]
20. Improving on-treatment risk stratification of cancer patients with refined response classification and integration of circulating tumor DNA kinetics.
Lv J; Wu C; Li J; Chen F; He S; He Q; Zhou G; Ma J; Sun Y; Wei D; Lin L
BMC Med; 2022 Aug; 20(1):268. PubMed ID: 35996151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
